A new form of treatment known as CAR-T cell therapy has been making waves in the field of oncology, and clinical trials have begun for patients with Malignant Pleural Mesothelioma (MPM).
Novartis’ anticipated leukemia treatment Kymriah is the first gene therapy to receive U.S. marketing clearance.
The U.S. FDA approved Genentech’s Actemra (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome in patients 2 years of age and older.
Gilead Sciences agreed to buy Kite Pharma in a nearly $12 billion deal as it looks to replace flagging sales from hepatitis C drugs via cancer immunotherapies.
Kite Pharma noted the publication of data related to its anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for aggressive non-Hodgkin’s lymphoma, including diffuse large B-cell lymphoma.
A U.S. Food and Drug Administration advisory panel unanimously recommended approval of Novartis AG’s CAR-T therapeutic, CTL019 (tisagenlecleucel), for B-cell acute lymphoblastic leukemia.
The U.S. Food and Drug Administration will ask a panel of advisors to focus on the safety of Novartis AG’s experimental gene therapy drug when it meets to review the product.
Novartis signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.
2016 Annual Report: Top 10 Pipelines
"Bad" LDL Cholesterol, Alzheimer's Diseases, Approvals, Big Pharma, Biologics License Application (BLA), Biosimilars, Biotech, Biotech/Biopharma, Biotechnology, Bispecific CD19-directed CD3 T cell engager (BiTE) antibodies, Blockbusters, Blood Cancers, Breakthrough Designation, Breakthrough Therapy, Breakthrough Therapy Designation, Breakthrough Therapy Designation, Cells, Chimeric Antigen Receptor T Cell Therapy (CART), Cholesterol, Chronic Lymphocytic Leukemia, Clinical Trials, Collaboration, Collaborations, Collaborations, Cystic Fibrosis, Deals, Diabetes, DNA, EGFR Inhibitors, Europe, European Commission, FDA, FDA/Regulatory, February 2016, Glucagon-Like Peptide-1 (GLP-1) Analogs, Immune Response, Immune System, Immune Systems, Immunotherapies, Influenza, Inhalers, Issue Archives, Mantle Cell Lymphoma (MCL), Monoclonal Antibodies, Multiple Myeloma, NDA, Neuroscience, New Drug Application (NDA), New Molecular Entities, Non-Small Cell Lung Cancer, Oncology, Pain, Parkinson's, Parkinson's Disease, Plaque Psoriasis, Potential Blockbusters, Psoriasis, R&D, Sales, SGLT2 Inhibitors, Special Reports, Specialty Therapy, Technology, TGF-Beta Inhibitors, The New England Journal of Medicine (NEJM), Therapeutics, Top 10 Pipelines, Transforming Growth Factor-beta (TGFb), Type 1 Diabetes, Type 2 Diabetes, Vaccines, Waldenstrom’s macroglobulinemiaThe pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
Novartis: Lymphoma study shows CART on track for 2017 U.S. submission
Analysts, B Cell Lymphomas, B Cells, Blood Cancers, Cells, Chimeric Antigen Receptor T Cell Therapy (CART), Diffuse large B-cell lymphoma (DLBCL), FDA, FDA/Regulatory, Follicular Lymphoma, Gene Therapy, Health, Immune System, Immune Systems, Leukemia, Leukemia, New Drug Application (NDA), Oncology, Pricing, Studies, T-CellsSwiss drugmaker Novartis said the latest findings from a study on its newest therapy for two kinds of blood cancer track earlier results, bolstering its confidence in a 2017 U.S. regulatory submission. Novartis is testing CTL019, its investigational chimeric antigen receptor T cell therapy, or CART, on 15 adult patients with the most-common non-Hodgkins […]
